[HTML][HTML] Dipeptidyl peptidase (DPP)-IV inhibitors with antioxidant potential isolated from natural sources: A novel approach for the management of diabetes

AK Singh, D Yadav, N Sharma, JO ** - Pharmaceuticals, 2021 - mdpi.com
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia that is predominantly
caused by insulin resistance or impaired insulin secretion, along with disturbances in …

[HTML][HTML] Therapeutic perspectives of CD26 inhibitors in imune-mediated diseases

X Hu, X Wang, X Xue - Molecules, 2022 - mdpi.com
The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in
multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the …

DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice

AB Herman, D Tsitsipatis, C Anerillas… - The Journal of clinical …, 2023 - jci.org
Senescent vascular smooth muscle cells (VSMCs) accumulate in the vasculature with age
and tissue damage and secrete factors that promote atherosclerotic plaque vulnerability and …

Targeting Senescent Cells in Atherosclerosis: Pathways to Novel Therapies

Y Tian, S Shao, H Feng, R Zeng, S Li… - Ageing Research Reviews, 2024 - Elsevier
Targeting senescent cells has recently emerged as a promising strategy for treating age-
related diseases, such as atherosclerosis, which significantly contributes to global …

[HTML][HTML] The anti-inflammatory effect of Novel Antidiabetic agents

P Theofilis, M Sagris, E Oikonomou, AS Antonopoulos… - Life, 2022 - mdpi.com
The incidence of type 2 diabetes (T2DM) has been increasing worldwide and remains one
of the leading causes of atherosclerotic disease. Several antidiabetic agents have been …

The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction

MT Wang, SC Lin, PL Tang, WT Hung… - Cardiovascular …, 2017 - Springer
Background Previous studies regarding the cardioprotective effects of dipeptidyl peptidase 4
(DPP-4) inhibitors have not provided sufficient evidence of a relationship between DPP-4 …

The regulatory role of DPP4 in atherosclerotic disease

L Duan, X Rao, C **a, S Rajagopalan… - Cardiovascular diabetology, 2017 - Springer
The increasing prevalence of atherosclerosis has become a worldwide health concern.
Although significant progress has been made in the understanding of atherosclerosis …

DPP-4 inhibitor linagliptin ameliorates oxidized LDL-induced THP-1 macrophage foam cell formation and inflammation

H Wang, Y Li, X Zhang, Z Xu, J Zhou… - Drug Design …, 2020 - Taylor & Francis
Introduction Atherosclerosis is one of the major causes of cardiovascular diseases. Lipid
uptake and accumulation in macrophages play a major role in atherosclerotic plaque …

Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options

MA Potenza, C Nacci, MA De Salvia, L Sgarra… - Pharmacological …, 2017 - Elsevier
The association of obesity and diabetes, termed “diabesity”, defines a combination of
primarily metabolic disorders with insulin resistance as the underlying common …

The protective effects of saxagliptin against lipopolysaccharide (LPS)-induced inflammation and damage in human dental pulp cells

X Guo, J Chen - Artificial Cells, Nanomedicine, and Biotechnology, 2019 - Taylor & Francis
Bacteria play a pivotal role in the pathological initiation and progression of pulpitis.
Lipopolysaccharide (LPS) is recognized as a major component of the outer wall of Gram …